CD8A and neoplasm: The synergistic effect of DOX and PD-L1 peptide blockade led to tumor clearance 60 days after the first subcutaneous inoculation of CT26 cancer cells in mouse flank accompanied by an activated immune response, including enhanced CD8+ T cell and downregulated CD25+ Tregs.